NO20060678L - Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer - Google Patents
Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorerInfo
- Publication number
- NO20060678L NO20060678L NO20060678A NO20060678A NO20060678L NO 20060678 L NO20060678 L NO 20060678L NO 20060678 A NO20060678 A NO 20060678A NO 20060678 A NO20060678 A NO 20060678A NO 20060678 L NO20060678 L NO 20060678L
- Authority
- NO
- Norway
- Prior art keywords
- optionally substituted
- alkyl
- alkyloxy
- polyhaloci
- polyhaloc
- Prior art date
Links
- 239000003572 glycogen synthase kinase 3 inhibitor Substances 0.000 title 1
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 title 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Denne oppfinnelse vedrører en forbindelse med formel etN-oksid, et farmasøytisk akseptabelt addisjonssalt, et kvatemært amin og en stereokjemisk isomer form derav, hvori ring A representerer fenyl, pyridyl, pyrimidinyl, pyridazinyl eller pyrazinyl; R' representerer hydrogen; aryl; formyl; Ci.6alkylkarbonyl; Ci.6alkyl; Ci.6alkyloksykarbonyl; Ci.6alkyl substituert med formyl, Ci.6aUcyULarbonyl, Ci.6aUsyloksykarbonyl, Ci.6aUcylkarbonyloksy; eUer Ci-ealkyloksyCi-ealkylkarbonyl eventuelt substituert med Ci-ealkyloksykarbonyl; X representerer en direktebinding; -(CH2)n3- eller -(CH2)n4-Xia-Xib-; R^ representerer Cs-vcykloalkyl; fenyl; en 4, 5, 6- eller 7- leddet monocyklisk heterocykel inneholdende minst ett heteroatom valgt fra O, S eller N; benzoksazolyl eller et radikal med formel hvori R^ -substituenten eventuelt kan være substituert; R^ representerer halo; hydroksy; eventuelt substituert Ci.6aUcyl; C2.6aUcenyl eUer C2.6alkynyl, hver eventuelt substituert; eventuelt substituert polyhaloCi-eaUcyl; eventuelt substituert Ci-eaUcyloksy; eventuelt substituert polyhaloCi-ealkyloksy; Ci-ealkyltio; polyhaloCi-eaUcyltio; Ci-eaUcyl-oksykarbonyl; Ci-ealkyUcarbonyloksy; Ci-ealkyUcarbonyl; polyhaloCi-eaULyUcarbonyl; cyano; karboksyl; aiyloksy; aiyltio; aiyUcarbonyl; NR^R^^; C(=0)-NR^'^; -NR'-C(=0)-NR'^*; -NR'-C(=0)-R'; -S(=0)bi,-R^ -NR'-S(=0>,i- R**; -S-CN; -NR^-CN; R'^ representerer hydrogen; halo; hydroksy; eventuelt substituert Ci.4aUsyl; C2.4aUcenyl eller C2.4aUcynyl, hver eventuelt substituert; polyhaloCualkyl; eventuelt substituert Ci.4alkyloksy; polyhalo-CuaUsyloksy; Ci.4alkyltio; polyhaloCi.salkyltio; Ci.4alkyloksykarbonyl; Ci.4alkyULarbonyloksy; Ci.4alkyULarbonyl; polyhaloCi.4aUcyl-karbonyl; nitio; cyano; karboksyl; NR'°R"; C(=0)NR'°R"; -NR'-C(=0)-NR'°R"; -NR'-C(-0)-R'; -S(=0)ni-R''; -NR'-S(=0)ni-R''; -S-CN; -NR'-CN; deres anvendelse, farmasøytiske sammensetninger omfattende dem og fremgangsmåter for deres fremstiUing.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0350310 | 2003-07-16 | ||
| PCT/EP2004/051455 WO2005012307A1 (en) | 2003-07-16 | 2004-07-12 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060678L true NO20060678L (no) | 2006-02-10 |
Family
ID=34112425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060678A NO20060678L (no) | 2003-07-16 | 2006-02-10 | Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7560458B2 (no) |
| EP (1) | EP1658292B1 (no) |
| JP (1) | JP2009514782A (no) |
| KR (1) | KR20060120393A (no) |
| CN (1) | CN100404536C (no) |
| AP (1) | AP2006003486A0 (no) |
| AR (1) | AR045698A1 (no) |
| AT (1) | ATE370142T1 (no) |
| AU (1) | AU2004260738B2 (no) |
| BR (1) | BRPI0412596A (no) |
| CA (1) | CA2531333A1 (no) |
| DE (1) | DE602004008303T2 (no) |
| DK (1) | DK1658292T3 (no) |
| EA (1) | EA010109B1 (no) |
| ES (1) | ES2290754T3 (no) |
| IL (1) | IL173139A (no) |
| JO (1) | JO2460B1 (no) |
| MX (1) | MXPA06000540A (no) |
| NO (1) | NO20060678L (no) |
| NZ (1) | NZ545058A (no) |
| PA (1) | PA8607001A1 (no) |
| PL (1) | PL1658292T3 (no) |
| PT (1) | PT1658292E (no) |
| TW (1) | TW200524935A (no) |
| WO (1) | WO2005012307A1 (no) |
| ZA (1) | ZA200600385B (no) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| JP2006514989A (ja) | 2002-07-29 | 2006-05-18 | ライジェル ファーマシューティカルズ | ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法 |
| PT1658292E (pt) * | 2003-07-16 | 2007-10-25 | Janssen Pharmaceutica Nv | Derivados de triazolpirimidina como inibidores da cinase 3 da síntase de glicogénio |
| US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| DK2287156T3 (da) * | 2003-08-15 | 2013-08-26 | Novartis Ag | 2,4-Di(phenylamino)-pyrimidiner egnede i behandling af neoplastiske sygdomme, inflammatoriske lidelser og lidelser i immunsystemet |
| US7129244B2 (en) * | 2003-09-18 | 2006-10-31 | Conforma Therapeutics Corporation | Triazolopyrimidines and related analogs as HSP90-inhibitors |
| CA2580855A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| JP5043668B2 (ja) | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| EP1799664A1 (en) | 2004-09-20 | 2007-06-27 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| AU2005329423A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
| CA2580844A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase |
| EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1807430B1 (en) | 2004-10-29 | 2014-07-23 | Janssen R&D Ireland | Hiv inhibiting bicyclic pyrimidine derivatives |
| WO2006076442A2 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives |
| WO2007130075A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| CN105348203B (zh) * | 2005-06-08 | 2018-09-18 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| CA2642229C (en) | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| AR067354A1 (es) | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
| EP2167497A2 (en) * | 2007-06-29 | 2010-03-31 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| RU2528386C2 (ru) | 2010-05-21 | 2014-09-20 | Кемилиа Аб | Новые производные пиримидина |
| AU2012230229A1 (en) | 2011-03-24 | 2013-10-10 | Noviga Research Ab | Novel pyrimidine derivatives |
| CN104066734B (zh) | 2012-01-28 | 2017-03-29 | 默克专利股份公司 | 三唑并[4,5‑d]嘧啶衍生物 |
| CA2866450C (en) | 2012-03-07 | 2020-02-18 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| WO2014135245A1 (en) | 2013-03-05 | 2014-09-12 | Merck Patent Gmbh | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| JP6427115B2 (ja) * | 2013-03-05 | 2018-11-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 癌などの疾患の処置のためのトリアゾロ［４，５−ｄ］ピリミジン誘導体 |
| WO2014180524A1 (en) | 2013-05-06 | 2014-11-13 | Merck Patent Gmbh | Macrocycles as kinase inhibitors |
| WO2016087665A2 (en) * | 2014-12-05 | 2016-06-09 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating cystic fibrosis |
| WO2017035528A1 (en) | 2015-08-27 | 2017-03-02 | Nantneuro, Llc | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| US11203576B2 (en) | 2016-03-11 | 2021-12-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5962594A (ja) * | 1982-09-30 | 1984-04-10 | Ss Pharmaceut Co Ltd | ３，５―ジ置換―トリアゾロピリミジン誘導体 |
| US20020040031A1 (en) * | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system |
| US6737085B2 (en) * | 2000-11-01 | 2004-05-18 | Tokiwa Phytochemical Co., Ltd. | Apocynum venetum extract for use as antidepressant |
| EP1347972A1 (en) * | 2000-12-19 | 2003-10-01 | Smithkline Beecham Plc | Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors |
| PT1658292E (pt) * | 2003-07-16 | 2007-10-25 | Janssen Pharmaceutica Nv | Derivados de triazolpirimidina como inibidores da cinase 3 da síntase de glicogénio |
-
2004
- 2004-07-12 PT PT04766189T patent/PT1658292E/pt unknown
- 2004-07-12 BR BRPI0412596-7A patent/BRPI0412596A/pt not_active IP Right Cessation
- 2004-07-12 JP JP2006519926A patent/JP2009514782A/ja not_active Withdrawn
- 2004-07-12 KR KR1020057024541A patent/KR20060120393A/ko not_active Ceased
- 2004-07-12 DK DK04766189T patent/DK1658292T3/da active
- 2004-07-12 AU AU2004260738A patent/AU2004260738B2/en not_active Ceased
- 2004-07-12 US US10/564,844 patent/US7560458B2/en not_active Expired - Fee Related
- 2004-07-12 AP AP2006003486A patent/AP2006003486A0/xx unknown
- 2004-07-12 NZ NZ545058A patent/NZ545058A/en not_active IP Right Cessation
- 2004-07-12 DE DE602004008303T patent/DE602004008303T2/de not_active Expired - Lifetime
- 2004-07-12 ES ES04766189T patent/ES2290754T3/es not_active Expired - Lifetime
- 2004-07-12 CN CNB2004800201486A patent/CN100404536C/zh not_active Expired - Fee Related
- 2004-07-12 CA CA002531333A patent/CA2531333A1/en not_active Abandoned
- 2004-07-12 EA EA200600258A patent/EA010109B1/ru not_active IP Right Cessation
- 2004-07-12 EP EP04766189A patent/EP1658292B1/en not_active Expired - Lifetime
- 2004-07-12 WO PCT/EP2004/051455 patent/WO2005012307A1/en active IP Right Grant
- 2004-07-12 MX MXPA06000540A patent/MXPA06000540A/es active IP Right Grant
- 2004-07-12 PL PL04766189T patent/PL1658292T3/pl unknown
- 2004-07-12 AT AT04766189T patent/ATE370142T1/de active
- 2004-07-12 JO JO200496A patent/JO2460B1/en active
- 2004-07-15 AR ARP040102496A patent/AR045698A1/es not_active Application Discontinuation
- 2004-07-15 PA PA20048607001A patent/PA8607001A1/es unknown
- 2004-07-15 TW TW093121066A patent/TW200524935A/zh unknown
-
2006
- 2006-01-12 IL IL173139A patent/IL173139A/en not_active IP Right Cessation
- 2006-01-13 ZA ZA200600385A patent/ZA200600385B/en unknown
- 2006-02-10 NO NO20060678A patent/NO20060678L/no not_active Application Discontinuation
-
2008
- 2008-09-16 US US12/211,361 patent/US20090036471A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW200524935A (en) | 2005-08-01 |
| AP2006003486A0 (en) | 2006-02-28 |
| AR045698A1 (es) | 2005-11-09 |
| WO2005012307A1 (en) | 2005-02-10 |
| KR20060120393A (ko) | 2006-11-27 |
| EP1658292A1 (en) | 2006-05-24 |
| JO2460B1 (en) | 2009-01-20 |
| ES2290754T3 (es) | 2008-02-16 |
| PA8607001A1 (es) | 2005-05-10 |
| MXPA06000540A (es) | 2006-03-30 |
| CN100404536C (zh) | 2008-07-23 |
| BRPI0412596A (pt) | 2006-09-19 |
| US7560458B2 (en) | 2009-07-14 |
| PT1658292E (pt) | 2007-10-25 |
| EA010109B1 (ru) | 2008-06-30 |
| DE602004008303T2 (de) | 2008-05-08 |
| AU2004260738A1 (en) | 2005-02-10 |
| AU2004260738B2 (en) | 2009-07-16 |
| PL1658292T3 (pl) | 2008-01-31 |
| DE602004008303D1 (de) | 2007-09-27 |
| US20090036471A1 (en) | 2009-02-05 |
| EA200600258A1 (ru) | 2006-06-30 |
| IL173139A (en) | 2010-04-29 |
| JP2009514782A (ja) | 2009-04-09 |
| CA2531333A1 (en) | 2005-02-10 |
| ATE370142T1 (de) | 2007-09-15 |
| NZ545058A (en) | 2008-05-30 |
| US20060205721A1 (en) | 2006-09-14 |
| ZA200600385B (en) | 2007-05-30 |
| IL173139A0 (en) | 2006-06-11 |
| EP1658292B1 (en) | 2007-08-15 |
| DK1658292T3 (da) | 2007-11-12 |
| CN1823068A (zh) | 2006-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060678L (no) | Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer | |
| WO2005012304A3 (en) | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| DK1442019T3 (da) | Amidderivater som glycogensynthasekinase 3- beta-inhibitorer | |
| CO6241157A2 (es) | "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9" | |
| CY1112642T1 (el) | Παραγωγα 4-(πυριδιν-4-υλο)-1η-[1,3,5]τριαζιν-2-ονης ως αναστολεις της gsκ3-βετα για τη θεραπεια των νευροεκφυλιστικων ασθενειων | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| NO20041911L (no) | Heteroarylaminer som glykogensyntase-kinase 3beta-inhibitorer (GSK3-inhibitorer) | |
| MX2021009763A (es) | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| NO2012010I2 (no) | Rilpivirin samt farmasøytisk akseptable addisjonssalter derav innbefattende hydrokloridsaltet av Rilpivirin | |
| WO2008007123A3 (en) | Pharmaceutical compounds | |
| NO20073960L (no) | Pyrazolderivater for inhibering av CDK og GSK | |
| ES2121223T3 (es) | Derivados de indol como antagonistas de tromboxano a2. | |
| TN2012000033A1 (en) | Mixtures of mesoionic pesticides | |
| MY139335A (en) | Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists | |
| GB0226724D0 (en) | Therapeutic agents | |
| AR066911A1 (es) | Derivados de piperidina / piperazina | |
| CY1114767T1 (el) | Ν,ν-υποκατεστημενες ενωσεις 3-αμινοπυρρολιδινης χρησιμες ως αναστολεις επαναπροσληψης μονοαμινων | |
| NO20071234L (no) | Forbindelser som potensierer glutamatreseptor og anvendelse derav innen medisin | |
| BR0211887A (pt) | Derivados de triazolil 2-amino-4,5-trissubstituìdo | |
| AR066154A1 (es) | Derivados de piperidina / piperazina | |
| CY1110502T1 (el) | Αντιμυκητικες 4-υποκατεστημενες 5,6-διϋδρο-4η-πυρρολο[1,2-α][1,4]βενζοδιαζεπινες | |
| MX373022B (es) | Inhibidores de kv1.3 y su aplicacion medica. | |
| CO2020012353A2 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |